CA2537978C - Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase - Google Patents

Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase Download PDF

Info

Publication number
CA2537978C
CA2537978C CA2537978A CA2537978A CA2537978C CA 2537978 C CA2537978 C CA 2537978C CA 2537978 A CA2537978 A CA 2537978A CA 2537978 A CA2537978 A CA 2537978A CA 2537978 C CA2537978 C CA 2537978C
Authority
CA
Canada
Prior art keywords
chloro
cyano
anilino
compound
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2537978A
Other languages
English (en)
Other versions
CA2537978A1 (fr
Inventor
Allan Wissner
Sridhar Krishna Rabindran
Hwei-Ru Tsou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2537978(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2537978A1 publication Critical patent/CA2537978A1/fr
Application granted granted Critical
Publication of CA2537978C publication Critical patent/CA2537978C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (1), présentant la structure (I), dans laquelle R¿1?, R¿2? et R¿3? désignent des éléments décrits dans la partie descriptive de la présente demande. Ces composés agissent comme des agents anticancéreux et inhibent HER-2 et EGFR.
CA2537978A 2003-09-15 2003-10-15 Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase Expired - Lifetime CA2537978C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15
US10/662,273 2003-09-15
PCT/US2003/032612 WO2005034955A1 (fr) 2003-09-15 2003-10-15 Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase

Publications (2)

Publication Number Publication Date
CA2537978A1 CA2537978A1 (fr) 2005-04-21
CA2537978C true CA2537978C (fr) 2011-08-02

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2537978A Expired - Lifetime CA2537978C (fr) 2003-09-15 2003-10-15 Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase

Country Status (7)

Country Link
EP (1) EP1670473A1 (fr)
AU (1) AU2003304497B2 (fr)
BR (1) BR0318503A (fr)
CA (1) CA2537978C (fr)
MX (1) MXPA06002846A (fr)
UA (1) UA85394C2 (fr)
WO (1) WO2005034955A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
WO2006127207A1 (fr) * 2005-05-25 2006-11-30 Wyeth Procede pour synthetiser des 3-cyanoquinoleines substituees et des produits intermediaires
EP3488866A1 (fr) 2005-11-04 2019-05-29 Wyeth LLC Combinaisons antinéoplasiques avec inhibiteur de mtor, d'herceptine et/ou hki-272
RS51483B (en) * 2006-04-14 2011-04-30 Astrazeneca Ab 4-ANILOXOQINOLINE-3-CARBOXamide KAO INHIBITOR CSF-1R Kinase
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3443961B1 (fr) 2008-06-17 2020-10-28 Wyeth LLC Combinaisons antinéoplasiques contenant du hki-272 et de la vinorelbine
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
CN101723854A (zh) 2008-10-24 2010-06-09 上海特化医药科技有限公司 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体
CA2755789C (fr) 2009-04-06 2016-01-19 Wyeth Llc Regime de traitement a l'aide de neratinib pour un cancer du sein
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (zh) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-氰基-6-氨基喹啉类衍生物、其制备方法及其在医药上的应用
EP2688565A1 (fr) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Traitement des troubles de la prolifération
CN102718679B (zh) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 一种诺那替尼关键中间体的制备方法
CN102731395B (zh) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 抗肿瘤药物来那替尼的中间体及其制备与应用
HUE033177T2 (en) 2012-01-17 2017-11-28 Astellas Pharma Inc Pyrazine is a carboxamide compound
CN104926669A (zh) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 反式-4-二甲基胺基巴豆酸盐酸盐的制备方法
JP7333313B2 (ja) * 2017-09-01 2023-08-24 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有複素環化合物、製造方法、中間体、組成物および使用
CN110357854A (zh) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 一种来那替尼的制备方法
CN111848581B (zh) * 2020-08-19 2021-08-10 昆明学院 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法
CN111943933B (zh) * 2020-09-02 2021-05-28 重庆医科大学 一种来那替尼杂质d的制备方法
CN111995618B (zh) * 2020-09-02 2021-06-11 重庆医科大学 一种来那替尼杂质g的制备方法
CN114920695B (zh) * 2022-06-29 2023-06-20 深圳大学总医院 一种喹唑啉衍生物及其制备方法、药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
NZ533118A (en) * 2001-11-27 2006-07-28 Wyeth Corp 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases

Also Published As

Publication number Publication date
EP1670473A1 (fr) 2006-06-21
WO2005034955A1 (fr) 2005-04-21
UA85394C2 (ru) 2009-01-26
CA2537978A1 (fr) 2005-04-21
MXPA06002846A (es) 2006-06-14
BR0318503A (pt) 2006-09-12
AU2003304497B2 (en) 2010-06-24
AU2003304497A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
US7399865B2 (en) Protein tyrosine kinase enzyme inhibitors
CA2537978C (fr) Utilisation de quinolines substituees comme inhibiteurs de la tyrosine kinase
EP1117659B1 (fr) Inhibiteurs de proteines de type tyrosine kinases a base de 3-cyanoquinolines substituees
EP1448531B1 (fr) 3-cyanoquinolines en tant qu'inhibiteurs de kinases egf-r et her2
US6002008A (en) Substituted 3-cyano quinolines
US7304059B2 (en) Substituted quinazolin-4-ylamine analogues
US6288082B1 (en) Substituted 3-cyanoquinolines
EP2125777B1 (fr) Composés substitués de spiro comme inhibiteurs d'angiogenèse
DE69733008T2 (de) Chinazolinderivate als antitumormittel
JP2001519788A (ja) 置換３−シアノキノリン
WO2008112407A1 (fr) Composés substitués de spiro comme inhibiteurs d'angiogenèse
EP1883630A2 (fr) Procedes de synthese de derives de 6-alkylaminoquinoline
SK287767B6 (sk) Substituovaný derivát 3-kyanochinolínu
JP2004517059A (ja) 抗腫瘍剤用の４−置換キノリン類
BRPI0318503B1 (pt) Quinolinas substituídas e composição farmacêutica compreendendo as mesmas

Legal Events

Date Code Title Description
EEER Examination request